vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $13.5M, roughly 1.7× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -416.2%, a 441.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 13.6%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-69.4M). Over the past eight quarters, UNITED SECURITY BANCSHARES's revenue compounded faster (3.0% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
NTLA vs UBFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $13.5M |
| Net Profit | $-95.8M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | 31.5% |
| Net Margin | -416.2% | 25.2% |
| Revenue YoY | 78.8% | 13.6% |
| Net Profit YoY | 25.7% | 36.8% |
| EPS (diluted) | $-0.81 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $13.5M | ||
| Q3 25 | $13.8M | $14.0M | ||
| Q2 25 | $14.2M | $12.6M | ||
| Q1 25 | $16.6M | $13.7M | ||
| Q4 24 | $12.9M | $11.9M | ||
| Q3 24 | $9.1M | $13.8M | ||
| Q2 24 | $7.0M | $13.0M | ||
| Q1 24 | $28.9M | $12.8M |
| Q4 25 | $-95.8M | $3.4M | ||
| Q3 25 | $-101.3M | $4.0M | ||
| Q2 25 | $-101.3M | $2.2M | ||
| Q1 25 | $-114.3M | $2.7M | ||
| Q4 24 | $-128.9M | $2.5M | ||
| Q3 24 | $-135.7M | $3.8M | ||
| Q2 24 | $-147.0M | $4.3M | ||
| Q1 24 | $-107.4M | $4.2M |
| Q4 25 | -428.9% | 31.5% | ||
| Q3 25 | -808.9% | 40.3% | ||
| Q2 25 | -772.2% | 24.0% | ||
| Q1 25 | -726.6% | 27.5% | ||
| Q4 24 | -1059.9% | 27.5% | ||
| Q3 24 | -1589.0% | 37.1% | ||
| Q2 24 | -1998.6% | 46.4% | ||
| Q1 24 | -394.0% | 45.9% |
| Q4 25 | -416.2% | 25.2% | ||
| Q3 25 | -735.2% | 28.7% | ||
| Q2 25 | -710.8% | 17.2% | ||
| Q1 25 | -687.6% | 19.6% | ||
| Q4 24 | -1001.2% | 20.9% | ||
| Q3 24 | -1489.5% | 27.7% | ||
| Q2 24 | -2112.6% | 33.0% | ||
| Q1 24 | -371.3% | 32.6% |
| Q4 25 | $-0.81 | $0.18 | ||
| Q3 25 | $-0.92 | $0.23 | ||
| Q2 25 | $-0.98 | $0.13 | ||
| Q1 25 | $-1.10 | $0.16 | ||
| Q4 24 | $-1.27 | $0.14 | ||
| Q3 24 | $-1.34 | $0.22 | ||
| Q2 24 | $-1.52 | $0.25 | ||
| Q1 24 | $-1.12 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $139.7M |
| Total Assets | $842.1M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $264.2M | ||
| Q3 25 | $511.0M | $211.1M | ||
| Q2 25 | $459.7M | $199.5M | ||
| Q1 25 | $503.7M | $198.4M | ||
| Q4 24 | $601.5M | $216.9M | ||
| Q3 24 | $658.1M | $216.8M | ||
| Q2 24 | $691.1M | $166.3M | ||
| Q1 24 | $791.3M | $168.6M |
| Q4 25 | $671.4M | $139.7M | ||
| Q3 25 | $748.4M | $137.4M | ||
| Q2 25 | $715.3M | $134.3M | ||
| Q1 25 | $779.9M | $132.9M | ||
| Q4 24 | $872.0M | $130.4M | ||
| Q3 24 | $962.6M | $132.9M | ||
| Q2 24 | $971.1M | $127.3M | ||
| Q1 24 | $1.0B | $124.2M |
| Q4 25 | $842.1M | $1.2B | ||
| Q3 25 | $925.3M | $1.2B | ||
| Q2 25 | $898.9M | $1.2B | ||
| Q1 25 | $986.2M | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.3B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $22.1M |
| Free Cash FlowOCF − Capex | $-69.4M | $19.8M |
| FCF MarginFCF / Revenue | -301.6% | 146.0% |
| Capex IntensityCapex / Revenue | 0.5% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $22.1M | ||
| Q3 25 | $-76.9M | $7.0M | ||
| Q2 25 | $-99.6M | $8.7M | ||
| Q1 25 | $-148.9M | $3.0M | ||
| Q4 24 | $-85.2M | $19.6M | ||
| Q3 24 | $-84.8M | $5.4M | ||
| Q2 24 | $-58.2M | $2.3M | ||
| Q1 24 | $-120.7M | $7.4M |
| Q4 25 | $-69.4M | $19.8M | ||
| Q3 25 | $-76.9M | $6.1M | ||
| Q2 25 | $-99.9M | $8.1M | ||
| Q1 25 | $-149.7M | $2.9M | ||
| Q4 24 | $-86.2M | $18.6M | ||
| Q3 24 | $-86.1M | $5.3M | ||
| Q2 24 | $-59.2M | $2.0M | ||
| Q1 24 | $-123.2M | $7.0M |
| Q4 25 | -301.6% | 146.0% | ||
| Q3 25 | -558.2% | 43.7% | ||
| Q2 25 | -701.0% | 64.3% | ||
| Q1 25 | -900.1% | 21.2% | ||
| Q4 24 | -669.4% | 156.0% | ||
| Q3 24 | -945.2% | 38.1% | ||
| Q2 24 | -850.9% | 15.5% | ||
| Q1 24 | -425.7% | 54.8% |
| Q4 25 | 0.5% | 16.8% | ||
| Q3 25 | 0.2% | 6.0% | ||
| Q2 25 | 1.7% | 4.6% | ||
| Q1 25 | 4.4% | 0.9% | ||
| Q4 24 | 7.6% | 8.7% | ||
| Q3 24 | 14.0% | 0.7% | ||
| Q2 24 | 14.5% | 2.2% | ||
| Q1 24 | 8.7% | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
UBFO
Segment breakdown not available.
